SYLVANT is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Janssen Biotech, Inc.. The primary component is Siltuximab.
Product ID | 57894-420_62686022-7ea4-11e8-8599-a18b9d46d017 |
NDC | 57894-420 |
Product Type | Human Prescription Drug |
Proprietary Name | SYLVANT |
Generic Name | Siltuximab |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2014-04-23 |
Marketing Category | BLA / BLA |
Application Number | BLA125496 |
Labeler Name | Janssen Biotech, Inc. |
Substance Name | SILTUXIMAB |
Active Ingredient Strength | 100 mg/1 |
Pharm Classes | Interleukin-6 Antagonist [EPC],Interleukin-6 Antagonists [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2014-04-23 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA125496 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2014-04-23 |
Marketing End Date | 2021-01-31 |
Ingredient | Strength |
---|---|
SILTUXIMAB | 100 mg/1 |
SPL SET ID: | 451f535b-8b6b-4ecf-9f19-d921b72eea39 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
57894-420 | SYLVANT | siltuximab |
57894-421 | SYLVANT | siltuximab |
73090-420 | Sylvant | Siltuximab |
73090-421 | Sylvant | Siltuximab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SYLVANT 86975538 4657836 Live/Registered |
JOHNSON & JOHNSON 2013-12-12 |
SYLVANT 86142160 not registered Dead/Abandoned |
JOHNSON & JOHNSON 2013-12-12 |
SYLVANT 77887266 not registered Dead/Abandoned |
JOHNSON & JOHNSON 2009-12-07 |